Nano-particle research will benefit inhaler-users

Patients suffering from conditions as diverse as asthma and diabetes could benefit from research at Cardiff University to
improve the effectiveness of drugs taken through spray inhalers.

Scientists in the Welsh School of Pharmacy are working on new nano-particle drug formulations for inhalers, and enhancers to
improve the effectiveness of proteins, such as insulin, delivered to the lung.

“Drugs delivered through inhalers are usually either in a suspension (as particles dispersed in liquid), or in a solution
(when the drug is dissolved in the liquid),” explained Dr James Birchall. “However, there are problems with both methods – a
suspension can lead to sediment in the inhaler and less of the drug reaching the target area of the lung, while solutions
present problems in dissolving the drug in the inhaler propellant liquid and can make the drug itself less stable.”

The Cardiff team’s approach is to prepare the drug in nano-particle form – ensuring the correct dosage reaches the lung and
the drug retains its stability, and providing the possibility of slowing the release of the drug in the lung for longer
therapeutic effect.

This could lead to the possibility of more drugs being administered effectively by inhaler, rather than by tablet or
injection.

Meanwhile, the team is also developing a process which uses a naturally occurring substance to enhance the absorption of
insulin. Initial studies suggest insulin is absorbed three to four times more effectively by this process.

Now Dr Birchall and his colleague Dr Glyn Taylor of The Pulmonary Research Group aim to combine the two innovations to
prolong and maximise the absorption effect.

“These two technologies could make a huge improvement in the effectiveness of spray inhalers for users suffering from a wide
range of illnesses and conditions,” said Dr Birchall.

Contact: Dr James Birchall
BirchallJCcardiff.ac
44-292-087-5815
Cardiff University
cardiff.ac

Using Botox To Treat Hypersalivation At The Montreal Children’s Hospital Of The MUHC

Botulinum toxin, also called Botox, is best known as one of the most commonly used molecules to reduce wrinkles. It is also known as one of the most poisonous naturally occurring substances.

Now, thanks to Dr. Sam Daniel, Associate Director of Research of the Otorhinolaryngology Division at the Montreal Children’s Hospital of the McGill University Health Centre, this protein has become an effective method to save newborns suffering from CHARGE Syndrome from having to undergo devastating tracheotomies. Dr. Daniel describes the case of the first infant patient treated with the toxin in an article from the Archives of Otolaryngology dated March 17th.

CHARGE Syndrome is rare, but it can become life-threatening in its most severe form. The syndrome includes a variety of birth defects in different organs, such as the heart, eyes or ears, but it also affects the salivary glands. They are hyper-stimulated and secrete excessive fluids that are discarded into the lungs, causing asphyxia. This was the case for the patient that Dr. Daniel discusses in his article: at the age of two and a half months, little Franck (not his real name) was still unable to breathe without assistance and a tracheotomy seemed inevitable in order to relieve his respiratory system.

Seeing the despair of Franck’s parents, Dr. Daniel proposed an experimental treatment as a last recourse: the injection of a minute dose of Botox into each of Franck’s salivary glands. This had never been done before on such a young child, but no other option could prevent permanent intubation. Two weeks after the injections, Franck’s extubation was a success. He now leads the normal life of a three-year-old boy at home with his parents.

Botulinum toxin is a very powerful neurotoxin, meaning that it blocks nerve activity. In Franck’s case, it blocked the nerves that stimulated his salivary glands thereby reducing their secretions to a normal level. The infant then needed repeated injections every four to six months for one and a half years until his glands shrunk and stopped overproducing saliva.

Since this first attempt 5 years ago, Dr. Daniel has performed over 1000 Botox injections in young children including 12 in newborns. “This treatment is extremely effective, and to date I have not encountered any major side effects despite the bad press Botox got recently. It also helps us considerably improve the lives of our patients,” he explained.

This release is available in French.

Dr Daniel has started sharing his expertise by training specialists in many hospitals around the world and in Canada. The interdisciplinary Saliva Management Clinic he founded at the MAB-MacKay Rehabilitation Centre, the first of its kind in Quebec, helps children and teens who are socially stigmatized and isolated because of their excessive drooling. It has recently celebrated its 3-year anniversary and has received an Award of Excellence for Innovation to acknowledge its development of novel methodologies and therapeutic/rehabilitative approaches for motor deficiencies. L’Association des ?©tablissements de r?©adaptation en d?©ficience physique du Qu?©bec (AERDPQ) presented the Centre with the award during its recent annual banquet.

Dr Sam Daniel is Associate Director of Research of the Otorhinolaryngology Division at the Montreal Children’s Hospital of the McGill University Health Centre, and Associate professor at McGill University,

The parents of the child mentioned in this press release have given us permission to tell their son’s story, but do not wish to make the child’s name public and they have declined the opportunity to do media interviews.

The McGill University Health Centre (MUHC) is a comprehensive academic health institution with an international reputation for excellence in clinical programs, research and teaching. The MUHC is a merger of five teaching hospitals affiliated with the Faculty of Medicine at McGill University – the Montreal Children’s, Montreal General, Royal Victoria, and Montreal Neurological Hospitals, as well as the Montreal Chest Institute. Building on the tradition of medical leadership of the founding hospitals, the goal of the MUHC is to provide patient care based on the most advanced knowledge in the health care field, and to contribute to the development of new knowledge. muhc/

The Research Institute of the McGill University Health Centre (RI MUHC) is a world-renowned biomedical and health-care hospital research centre. Located in Montreal, Quebec, the institute is the research arm of the MUHC, a university health center affiliated with the Faculty of Medicine at McGill University. The institute supports over 500 researchers, nearly 1000 graduate and post-doctoral students and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge, innovation and technology and is inextricably linked to the clinical programs of the MUHC, ensuring that patients benefit directly from the latest research-based knowledge. For further details visit: muhc/research.

The Montreal Children’s Hospital is the pediatric teaching hospital of the McGill University Health Centre (MUHC). The institution is a leader in the care and treatment of sick infants, children, and adolescents from across Quebec. The Montreal Children’s Hospital provides a high level and broad scope of health care services, and provides ultra specialized care in many fields including: cardiology and cardiac surgery; neurology and neurosurgery, traumatology; genetic research; psychiatry and child development and musculoskeletal conditions, including orthopedics and rheumatology. Fully bilingual and multicultural, the institution respectfully serves an increasingly diverse community in more than 50 languages. thechildren/

Source: Isabelle Kling

McGill University Health Centre

View drug information on Botox.

UK Government Boosts Funding For UNICEF To Improve Children’s Health And Education

The UK Government will almost double its core funding for UNICEF, after a recent aid review found the agency highly effective in delivering results to keep children healthy and ensure access to quality education.

“Nine organizations have been assessed as providing very good value for the British tax payer,” said Andrew Mitchell, UK’s Secretary of State for International Development. “UNICEF’s work to keep children healthy and ensure they have access to education enables them to demonstrate the kind of results that the British taxpayer can feel proud to have played a part in achieving.”

The British government’s annual contribution nearly doubled from 21 million pounds ($35.2 million) in 2010/2011to 40 million pounds ($65.3 million) in 2011/2012; the contribution is to core funding, which are non-earmarked donations allowing for rapid responses and flexibility in delivering assistance on the ground.

The Multilateral Aid Review, commissioned by the UK’s Department for International Development (DFID), assessed if the UK’s contributions to international organizations were yielding maximum results.

The review found that UNICEF was able to demonstrate “impressive results” in helping to tackle child mortality, maternal health issues, education and HIV/AIDS – all of which are closely aligned to the UK Government’s aid objectives.

The UK also noted that UNICEF delivers a number of programmes for children in conflict and fragile states. As a result of the aid review the UK Government is looking to expand its work in fragile states, 15 of which are among the 20 poorest in the world.

UNICEF’s Executive Director, Anthony Lake welcomed UK’s assistance to improve the lives of the world’s poorest and most vulnerable children.

“UNICEF is deeply grateful to the people of the United Kingdom for their generosity, and we will work hard to earn their continued confidence by delivering results for the children most in need.”

UNICEF has adopted an equity-based strategy focusing on the most vulnerable, to move more quickly and cost-effectively towards meeting the Millennium Development Goals of reducing child mortality and improving maternal health. The approach has a potential of averting millions of maternal and child deaths by 2015. In 2009, with UNICEF support, more than 140 million children were immunized against measles – 63 million in integrated campaigns that also distributed 13.3 million doses of de-worming medicine.

UNICEF will use the additional support from the UK Government to strengthen its efforts to further reduce child and maternal deaths by building stronger community-based public health interventions, especially in the poorest and remotest communities. UNICEF will also use this support to get more children into the classroom, improve the quality of education by training more teachers, and making what children learn more relevant to their lives.

The review also found that UNICEF had the potential to become even more effective by improving its leadership in humanitarian emergencies, working more closely with other UN agencies, and demonstrating its impact and efficiency to a greater extent.

Source:

UNICEF

Bill And Melinda Gates To Receive Honorary Degrees From Karolinska Institutet

Microsoft founder Bill Gates and his wife Melinda French Gates will receive honorary doctor of medicine degrees from Karolinska Institutet for their contributions to global health through the Bill & Melinda Gates Foundation. A special conferment ceremony will be arranged in Stockholm next January.

The honorary award is bestowed by the Board of Research at Karolinska Institutet. In their citation, the Board commends Bill and Melinda Gates for their active and long-term contributions through their foundation to improving human health where there is the greatest need. The Bill & Melinda Gates Foundation supports healthcare provision in poor countries and finances research to develop effective measures against the most serious global health problems.

“The Gates Foundation’s science-based approach to global health ensures that the money they contribute is put to the most effective use,” says Jan Carlstedt-Duke, Dean of Research at Karolinska Institutet.

The Bill & Melinda Gates Foundation has contributed almost $7.8 billion to date to support global health programs.

This year, Karolinska Institutet has appointed three additional honorary doctors (two in medicine and one in dentistry), who will be receiving the symbols of their new status (ring, diploma and cap) at the annual conferment ceremony in May in the Stockholm City Hall.

For further information, contact:

Professor Jan Carlstedt-Duke, Dean of Research

Karolinska Institutet is one of the leading medical universities in Europe. Through research, education and information, Karolinska Institutet contributes to improving human health. Each year, the Nobel Assembly at Karolinska Institutet awards the Nobel Prize in Physiology or Medicine. For more information, visit ki.se/

Bill and Melinda Gates Foundation

Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to reduce inequities and improve lives around the world. In developing countries, it focuses on improving health, reducing extreme poverty, and increasing access to technology in public libraries. In the United States, the foundation seeks to ensure that all people have access to a great education and to technology in public libraries. In its local region, it focuses on improving the lives of low-income families. Based in Seattle, the foundation is led by CEO Patty Stonesifer and Co-chairs William H. Gates Sr., Bill Gates, and Melinda French Gates. For more information, please visit gatesfoundation/

Contact: Sabina Bossi

Karolinska Institutet

Lung disease treatment may prevent heart attacks

Inhaled corticosteroids, drugs used to treat asthma and chronic obstructive pulmonary disease (COPD), were found to be
associated with a reduction in the risk of acute myocardial infarction, according to investigators at McGill University in
Montreal led by Samy Suissa.
Their findings, published in the April issue of the ERJ, show that low doses of these drugs used by patients with COPD may
reduce the risk of acute myocardial infarction by 30%.

COPD, characterised by slowly progressive and mostly irreversible airflow limitation, is the fourth leading cause of death in
the USA and Europe. COPD patients are more likely to develop cardiovascular disease.

Inhaled corticosteroids, drugs that target the inflammatory component of COPD, may also affect the inflammation present in
the development of cardiovascular disease.

The McGill University team looked at a cohort of 5,648 COPD patients identified using the Canadian province of Saskatchewan’s
universal health insurance programme. During an 8-year follow-up, 371 of these patients incurred an acute myocardial
infarction.

The authors found that the use of inhaled corticosteroids was generally associated with an 18% reduction in the risk of acute
myocardial infarction and a significant 32% reduction with lower doses.

The authors conclude that inhaled corticosteroids may lower the inherently elevated risk of heart attacks in patients with
COPD.

This potential unintended benefit of inhaled corticosteroids should be verified further using randomised controlled trials.

Title of the original article:
Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD

EUROPEAN RESPIRATORY JOURNAL (ERJ), Vol. 25, No 4
erj.ersjournals

Study To Reveal Workings Of Dementia Genes

University of Manchester scientists are to investigate the biological causes of the second most common form of dementia after Alzheimer’s, thanks to a prestigious ??1.9 million senior fellowship award from the Medical Research Council.

Frontotemporal lobar degeneration (FTLD) is a group of dementias that affect the frontal and temporal lobes of the brain and are characterised by behaviour and language dysfunction, rather than the memory loss associated with Alzheimer’s disease (AD).

FTLD, which affects about 50,000 people in the UK, also differs from AD in that it targets younger people: FTLD sufferers are usually in their 50s or 60s, although people as young as their 20s have also fallen victim to FTLD. AD sufferers tend to be older.

“Alzheimer’s patients lose their awareness of space and time, whereas FTLD can result in changes in personality as well as speech and language difficulties,” said Dr Stuart Pickering-Brown, who is leading the research.

“Sufferers can become apathetic or exhibit behaviour at the other extreme and lose normal social values which lead them to act inappropriately.

“Speech and language difficulties fall into two main types: sufferers can develop problems with grammar and pronunciation or have semantic dementia where they lose the information content of language.

Errors in two genes – tau and progranulin – have been identified as causes for FTLD but these only account for 10% of cases. The University of Manchester team plan to investigate the role other genes may play in the disease.

“Our research suggests other genes may be important in regulating the amount of tau and progranulin in the brain,” said Dr Pickering-Brown, who is based in the School of Translational Medicine.

“Progranulin is associated with wound healing and little is known about its function in the brain, so we now plan to study the effects of progranulin on cells and explore how it is affected by other genes.”

At the end of the five year study, the team hope to have a much clearer understanding of the genetic causes underlying FTLD.

“Understanding the biological problems that lead to FTLD will help in diagnosing the condition and ultimately allow us to find future therapies for patients.”

The Medical Research Council’s senior fellowship awards are aimed at independent researchers of exceptional ability. Only five such non-clinical awards were handed out this year across all fields of medical research.

Source: Aeron Haworth

University of Manchester

How training affects hormone to different modes of exercise

Contact: Donna Krupa
Phone 703.527.7357 Cell: 703.967.2751
djkrupa1aol

Can The Mode Of Training Affect The Hormone Response To Different
Modes Of Exercise?

First-of-its kind study concludes circulating endogenous hormone profile is more dependent on exercise mode or intensity than exercise volume as measured by caloric expenditure in men

(Bethesda, MD, USA) — There are a number of reasons why, in men, the manipulation of anabolic hormones (such as testosterone) and the anabolic/catabolic hormone ratio (e.g., testosterone/cortisol) might be beneficial.

From the perspective of an athlete, an increase in anabolic-androgenic hormones can improve performance by decreasing body fat and increasing lean body mass and muscular strength. Among older men, it may help to replace the decline in testosterone, which can negatively affect body composition and physical function.

Studies have shown that endurance-trained men tend to have lower levels of testosterone compared to their sedentary counterparts and that resistance-trained men have higher basal testosterone levels. Studies have also found that both endurance- and resistance-trained males had lower testosterone levels than sedentary control subjects.

Thus, while it is known that training status can influence the hormone response to exercise, it is not clear whether the mode of training can affect the hormone response to different modes of exercise. Such information could be useful in designing training regimes that will result in the most favorable ratio of anabolic and catabolic hormones.

A first-of-its-kind study attempts to determine the acute steroid hormone response to endurance and resistance exercise bouts of equitable volume in subjects with differing training status.

The newly released findings conclude that the circulating endogenous hormone profile is more dependent on exercise mode or intensity than on exercise volume as measured by caloric expenditure. The study also provides evidence that hormone levels and exercise-induced hormone changes are different in subjects of different training status.

A New Study

The authors of the study, entitled, “Effect of Training Status and Exercise Mode on Endogenous Steroid Hormones in Males,” are Mark S. Tremblay, Jennifer L. Copeland, and Walter Van Helder, all of the College of Kinesiology, University of Saskatchewan, Saskatoon, SK, Canada.

Their findings appear in the “Articles in Press” section of the Journal of Applied Physiology. The Journal of Applied Physiology is one of 14 scientific journals published each month by the American Physiological Society (APS).

Summary of Methodology

Twenty-two healthy males were recruited who were resistance-trained (RES, N=7), endurance-trained (END, N=8) or sedentary (SED, N=7). Each screened volunteer participated in four late afternoon sessions.

This time was chosen because it best represented the typical time period during which the subjects trained and because variation of testosterone is minimized during this period.

During session one, baseline anthropometric and fitness measurements were obtained. During session two subjects rested quietly. A resting blood sample was drawn at 0.5 hours and subsequent blood samples were drawn each hour for the subsequent four hours.

Plasma was analyzed for luteinizing hormone (LH), dehydroepiandrosterone sulfate (DHEAS), cortisol, and free and total testosterone. Endurance and resistance exercise bouts were completed during sessions three and four.

These exercise sessions were matched according to caloric expenditure (calculated from expired gases). Each testing session was separated by at least one week.

Height, body mass, and skinfold thickness were taken, and strength measurements were performed. Maximal aerobic power was determined using a progressive, incremental treadmill protocol. Minute ventilation (VE), oxygen consumption (VO2), carbon dioxide production (VCO2), and respiratory exchange ratio (RER) were monitored.

All data were presented as means ± standard deviation, and statistical significance was set at p

Genmab Announces Positive Interim Data For The HuMax-CD20 Phase II RA Study

Genmab A/S (CSE:
GEN) announced today positive results from an interim analysis of the first
100 patients in the ongoing Phase II rheumatoid arthritis (RA) study. A
statistically significant proportion of patients on active treatment
obtained a 20% improvement of the American College of Rheumatology (ACR)
response compared to patients treated with placebo. Correspondingly, in all
groups treated with HuMax-CD20, a greater proportion of patients benefited
from moderate or good EULAR responses compared to placebo.

Rates of overall adverse events were comparable between the 3 groups of
patients receiving HuMax-CD20 these were primarily infusion related and do
not limit plans for continued development. Serious infections among treated
patients were confined to one event of bronchopneumonia in the 300 mg dose
group.

With this data in hand, Genmab will start planning Phase III studies.
These studies are expected to begin in 2007.

“The interim data are comparable to the Phase I/II RA data trial
released earlier this year and support our plan to move into Phase III with
HuMax-CD20 in RA,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of
Genmab. “Our fully human antibody should be suitable for treating
chronically ill patients and we look forward to continued development of
this potential alternative to available treatments.”

There are 226 patients enrolled in the Phase II study which completed
accrual in September. Genmab expects to present results for the full Phase
II study during the first half of 2007. This analysis was carried out to
assist in decision making and planning for the expected Phase III studies
in RA.

About the study

The study is a double-blind, randomized, placebo controlled,
multicenter Phase II trial for patients with active RA who have previously
failed one or more DMARDs. Patients were randomized to one of 4 treatment
groups (300 mg, 700 mg or 1000 mg of HuMax-CD20 or placebo). Patients were
permitted to continue therapy with stable doses of methotrexate and low
dose prednisolone was also allowed. ACR and EULAR responses were assessed
in the primary intention-to-treat efficacy population at 24 weeks.

About Genmab A/S

Genmab A/S is a biotechnology company that creates and develops human
antibodies for the treatment of life-threatening and debilitating diseases.
Genmab has numerous products in development to treat cancer, infectious
disease, rheumatoid arthritis and other inflammatory conditions, and
intends to continue assembling a broad portfolio of new therapeutic
products. At present, Genmab has multiple partnerships to gain access to
disease targets and develop novel human antibodies including agreements
with Roche and Amgen. A broad alliance provides Genmab with access to
Medarex, Inc.’s array of proprietary technologies, including the UltiMAb(R)
platform for the rapid creation and development of human antibodies to
virtually any disease target. In addition, Genmab has developed
UniBody(TM), a new proprietary technology that creates a stable, smaller
antibody format. Genmab has operations in Copenhagen, Denmark, Utrecht, the
Netherlands, Princeton, New Jersey, US and Hertfordshire in the United
Kingdom. For more information about Genmab, visit genmab.

This press release contains forward-looking statements. The words
“believe,” “expect,” “anticipate,” “intend” and “plan” and similar
expressions identify forward-looking statements. Actual results or
performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability
to manage growth, the competitive environment in relation to our business
area and markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and
other factors. Genmab is not under an obligation to update statements
regarding the future following the publication of this release, nor to
confirm such statements in relation to actual results, unless this is
required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-
EGFr(TM); HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM),
HuMax-CD38(TM); and UniBody(TM) are all trademarks of Genmab A/S.

UltiMAb(R) is a trademark of Medarex, Inc.

Genmab A/S
genmab

First ever MDI with counter introduced to help asthma patients track their medication

Seretide Evohaler leads the way with a built-in counter –
The asthma combination treatment SeretideTM (salmeterol/fluticasone propionate) has been introduced in the world’s first ever
metered-dose inhaler (MDI) with a counter.

A recent study of children and their parents published in Chest found that three quarters of patients with asthma do not know
how many puffs are in their inhaler1 and two thirds of patients reported feeling anxious not knowing how much they have left
in their inhaler 2. Over a third of asthma patients also wait until their inhaler has run out completely before thinking
about replacing it.2

After 5 years in development, the new counter will enable Seretide patients to track whether they have taken their daily dose
more easily and ensure they know when to replace their inhaler. MDIs are the UK’s favourite asthma device and used by over
three-quarters of patients.3

“The counter may be miniature, but it will make a big difference,” commented Dr Carol Cooper, GP in west London. “As a
family doctor I welcome a device that has the benefits of an MDI plus a counter. It will help prevent patients from running
out of their inhaler without warning, which, as every GP knows, happens all too often at Christmas and other holiday times.”

She continued, “It should also prove beneficial to those who may have trouble remembering whether they took their treatment.
As the mum of a son with asthma, I know how hard it is for children and young people to keep up with regular use of their
inhalers, especially when they’re feeling well. This advance will give patients and their parents a useful method of checking
that the inhaler is used as prescribed.”

The Chest paper also reported that if patients have no way of knowing when an MDI is empty, they may continue to use the
medication for up to twice the intended duration.1 The authors concluded that until effective counters were added, counting
the number of individual doses would be the only accurate way of the patient telling when to discard an inhaler1, previous
studies have shown only 8% of patients currently do this.4

“It’s brilliant,” added Dr Tony Crockett, GP in Shrivenham and member of the General Practice Airways Group. “Patients won’t
run out of their inhaler and can plan when to get repeats. No-one will be able to use the excuse that their inhaler ran out
to explain why they stopped their treatment.”

The counter is new, but everything else is just the same. The new Seretide Evohaler works in exactly the same way as the
current MDI and is the same size and weight, with count accuracy of more than 99%. Counting down from 120 doses, patients
are recommended to get a replacement inhaler when the counter shows 20 and to stop using it when it shows 0. The new Seretide
Evohaler with counter will start replacing the existing Seretide Evohaler from December 2004. The price of Seretide Evohaler
has not changed.

For further information, please contact:

Lisa Marriott
Ketchum
(020) 7611 3691
lisa.marriottketchum

Katie Banks
Ketchum
(020) 7611 3619
katie.banksketchum

References

1. Rubin BK, Durotoye L. How do patients determine that their metered-dose inhaler is empty? Chest 2004; 126: 1134-1137.

2. GlaxoSmithKline data on file. SERT DOF 049.

3. GlaxoSmithKline data on file. SERT DOF 050. Percentage of patients in UK using MDI

4. Ogren RA, Baldwin JL, Simon RA. How patients determine when to replace their metered-dose inhalers. Ann Allergy Asthma
Immunol 1995; 75:485-489

Additional Import Controls In Place For Food Products From Japan, Canada

The Canadian Food Inspection Agency (CFIA), in collaboration with the Canada Border Services Agency (CBSA) and Health Canada, is implementing enhanced import controls on milk products, fruits, and vegetables from areas of Japan affected by the ongoing nuclear crisis (Japanese prefectures of Fukushima, Gunma, Ibaraki, and Tochigi).

These products will not be allowed entry into Canada without acceptable documentation verifying their safety. Any potentially contaminated products will be disposed of in accordance with protocols from the Canadian Nuclear Safety Commission.

The CFIA will continue to work closely with Japan, other trading partners and international organizations. Given the evolving nature of the Japanese situation, these measures will be adjusted, as warranted, to ensure the Canadian food supply remains protected.

The CFIA recognizes that the government of Japan is taking steps to address this issue and we will continue to provide support to their efforts.

The restrictions add an additional safeguard to Canada’s existing import controls. CFIA maintains rigorous controls and tracking systems for imported food, while CBSA routinely monitors radioactivity levels in shipping containers.

Source:

Canadian Food Inspection Agency (CFIA)